IMpower is a phase 3 study measuring the effect of carboplatin and paclital (CP) combined with atezolizumbab (A) and or bevacizumab (B) in patients with advanced non-squamous NSCLC.
The study demonstrated efficacy of ABCP regardless of PD-L1 status. Though high PD-L1 expression and immune phenotype, assessed via RNA-seq, was associated with increased benefit.
Increased benefit based on immune phenotype points to the importance of understanding factors in the tumor micro-environment that are predictive of benefit from immuno-oncology (IO) and VEGF inhibition.
